NeoADAURA: Neoadjuvant Osimertinib for Resectable EGFR-mutated NSCLC

The phase 3 NeoADAURA study evaluated the effectiveness of neoadjuvant osimertinib, with or without chemotherapy, in patients with resectable stage II–IIIB EGFR-mutated non–small cell lung cancer (NSCLC). It expanded on research from the phase 3 ADAURA study, which established adjuvant osimertinib as the standard of care for the same patient population.

The primary endpoint was major pathologic response by blinded central pathology review. Among 358 patients, the major pathologic response rate was 26% with osimertinib plus chemo, 25% with osimertinib alone, and only 2% with chemo alone. Event-free survival also favored the osimertinib arms. Surgery completion rates exceeded 89% in all groups. Grade ≥3 adverse events were more frequent with combination therapy but remained manageable.

Review more insights on the NeoADAURA study from Lung Cancers Today.

Read the full abstract from the 2025 ASCO Annual Meeting.